Dendreon Corp. (NASDAQ:DNDN), the maker of sipuleucel-T (Provenge), said it expects no impact on access to the prostate cancer immunotherapy following the company’s Chapter 11 filing last week. In a separate but related announcement, Bayer HealthCare said it has resumed production of its prostate cancer agent radium Ra 223 dichloride (Xofigo) following a production issue that led to a shortage of the drug. Dendreon Corp. (NASDAQ:DNDN) belongs to Healthcare sector. Its net profit margin is -70.70% and weekly performance is -84.60%. On last trading day company shares ended up $0.13. Dendreon Corp. (NASDAQ:DNDN) distance from 50-day simple moving average (SMA50) is -88.96%. Clovis Oncology, Inc. (NASDAQ:CLVS) announced that the Phase 2 portion of the seamless Phase 2/3 TIGER-1 (Third-Generation Inhibitor of Mutant EGFR in Lung Cancer) study has commenced with the dosing of the first patient at a U.S. study site. Rociletinib is the Company's novel, oral, targeted covalent (irreversible) mutant-selective inhibitor of the epidermal growth factor receptor (EGFR) for the treatment of non-small cell lung cancer (NSCLC) in patients with initial activating EGFR mutations as well as the primary resistance mutation T790M. Clovis Oncology, Inc. (NASDAQ:CLVS) shares moved down -2.81% in last trading session and ended the day at $56.80. CLVS return on assets is -20.60%. Clovis Oncology, Inc. (NASDAQ:CLVS) quarterly performance is 28.45%. CDW Corporation (NASDAQ:CDW)’s Director Steven W. Alesio purchased 7,500 shares of the stock on the open market in a transaction dated Friday, November 7th. The stock was purchased at an average price of $32.60 per share, with a total value of $244,500.00. On 13 November, CDW Corporation (NASDAQ:CDW) shares advanced 0.31% and was closed at $32.57. CDW EPS growth in last 5 year was 15.80%. CDW Corporation (NASDAQ:CDW) year to date (YTD) performance is 40.03%. Pacira Pharmaceuticals (NASDAQ:PCRX) CFO James S. Scibetta sold 15,000 shares of the stock on the open market in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $87.18, for a total transaction of $1,307,700.00. Following the completion of the sale, the chief financial officer now directly owns 5,000 shares of the company’s stock, valued at approximately $435,900. Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) ended the last trading day at $88.95. Company weekly volatility is calculated as 4.16% and price to cash ratio as 21.41. Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) showed a weekly performance of -1.39%. IMAX Corporation (NYSE:IMAX) and Toho Cinemas Ltd., Japan’s highest-grossing exhibition company and subsidiary of Toho Co. Ltd., the largest film production and distribution company in Japan, announced an agreement for an IMAX® theatre to be added to Toho’s new development in Shinjuku, the commercial, business and entertainment center of Tokyo. The new construction project will include a hotel, restaurants, retailers and the Toho Cinemas Shinjuku where IMAX will serve as the multiplex’s anchor entertainment attraction. The deal marks the Company’s first agreement with Toho Cinemas and the first IMAX theatre to be located in downtown Tokyo. IMAX Corporation (NYSE:IMAX) shares moved down -0.52% in last trading session and ended the day at $30.44. IMAX Gross Margin is 60.40% and its return on assets is 9.00%. IMAX Corporation (NYSE:IMAX) quarterly performance is 14.26%.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
